Aquinox Pharmaceuticals Inc. (AQXP) Rating Increased to Hold at Zacks Investment Research
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
Several other research analysts also recently issued reports on the company. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 21st. Jefferies Group lifted their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Finally, Leerink Swann began coverage on Aquinox Pharmaceuticals in a research note on Tuesday. They set an “outperform” rating and a $24.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $20.29.
Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 2.07% on Tuesday, reaching $14.22. 583,380 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $11.93 and a 200-day moving average price of $9.03. Aquinox Pharmaceuticals has a 1-year low of $6.01 and a 1-year high of $16.75. The company’s market capitalization is $244.75 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.22. On average, equities research analysts anticipate that Aquinox Pharmaceuticals will post ($2.23) earnings per share for the current year.
In related news, major shareholder Bros. Advisors Lp Baker acquired 2,783,605 shares of the company’s stock in a transaction that occurred on Tuesday, September 20th. The stock was purchased at an average price of $12.25 per share, for a total transaction of $34,099,161.25. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 3.00% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. boosted its stake in Aquinox Pharmaceuticals by 7.6% in the first quarter. Franklin Resources Inc. now owns 1,245,945 shares of the company’s stock worth $10,989,000 after buying an additional 87,600 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Aquinox Pharmaceuticals by 5,277.2% in the first quarter. Goldman Sachs Group Inc. now owns 970,317 shares of the company’s stock worth $8,558,000 after buying an additional 952,272 shares in the last quarter. Boxer Capital LLC boosted its stake in Aquinox Pharmaceuticals by 7.0% in the second quarter. Boxer Capital LLC now owns 877,753 shares of the company’s stock worth $5,811,000 after buying an additional 57,738 shares in the last quarter. BlackRock Advisors LLC boosted its stake in Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock worth $2,678,000 after buying an additional 8,280 shares in the last quarter. Finally, Opaleye Management Inc. bought a new stake in Aquinox Pharmaceuticals during the second quarter worth approximately $1,953,000. Hedge funds and other institutional investors own 68.20% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.